CRISPR and ALS

Brief Overview

CRISPR is a highly specific and efficient genome editing technology. CRISPR facilitates the addition, deletion, or alteration of an organism’s DNA (NIH). If you would like a more specific explanation of CRISPR, feel free to watch the 1:39 video from the Mayo Clinic below.

As one can imagine, this is exciting and simultaneously, terrifying technology. It holds incredible potential for countless rare, genetic diseases. The concept of curing a disease by removing a faulty gene, is not new, but CRISPR is definitely one of the more cost-effective and reliable ways to do so. Thus far, CRISPR technology has been tested on many rare disease areas, including cancers, sickle cell anemia, Huntington’s Disease, Alzheimer’s Disease, and ALS. In 2018, Target ALS provided CRISPR Therapeutics with a 2-year grant to study ALS and Frontotemporal Dementia (FTD). We are excitedly awaiting those results.

Current CRISPR Challenges

The success of CRISPR technology depends on the structural validity of in vivo disease models, meaning how well the animal model of the disease actually portrays the disease in humans. The ALS field has historically struggled with this issue. CRISPR success also depends on the capabilities of high throughput genome mapping technology, meaning, how much knowledge we have about the genome we will be editing. As we observe these two key elements (animal model validity and genome mapping technology) becoming more efficient and reliable, we will begin to see very obvious therapeutic results from CRISPR.

Another roadblock to CRISPR’s usage in ALS is the fact that sporadic ALS is a messy disease. Messy meaning there are often a number of genes that contribute to the disease manifestation. Not only that, but these genes are not all ‘bad’ genes, but they are mutated in some way. For example, the protein C9orF72 is indicated in both familial and sporadic ALS. The normal function of this gene is to “influence the production of RNA from genes, the production of proteins from RNA, and the transport of RNA within the cell” (NIH). In ALS, C9orF72 is expressed as a hexanucleotide repeat expansion. If you program CRISPR technology to eliminate C9orF72, you may eliminate ALS, but you will also eliminate all the normal function of the protein, which could be deadly.

CRISPR Breakthroughs

Treatment of a Mouse Model of ALS by In Vivo Base Editing

In this study done at the University of Illinois, ALS disease progression was slowed in mice when CRISPR was applied. Researchers utilized cytidine base editors (CBEs) to remove SOD1 gene expression. “CBEs are a type of CRISPR single-base editors that change specific nucleotide bases in a DNA sequence” (ALSNewsToday). The result of using this type of CRISPR technology is that it does not delete the SOD1 gene, but rather it induces a ‘stop’ signal early in the gene expression so that it cannot progress to be a mutant SOD1 gene. Very cool.

The most common CRISPR headline you will see in relation to ALS is this one:

CRISPR reveals possible ALS drug target

In this particular study, a research team at Stanford used CRISPR to effectively ‘knockout’ or cut random genes out of the genome so that they observe “genes that protect neurons against the toxic effects of protein aggregates by being inactivated” (FierceBiotech). Their study revealed that “knocking out a gene called TMX2 prevented cell health in mouse neurons.” In the ALS world right now, finding possible therapeutic targets is a huge deal and most researchers are hard at work knocking out genes to do so.

The final, and arguably the most exciting, CRISPR breakthrough is highlighted in these two articles:

CRISPR-based method allows for reversible RNA editing

RNA-targeting CRISPR could yield treatment for Huntington’s and ALS. 

The methodology behind this concept is mind-blowing. This article is from 2017, but they are still fine-tuning the science today. Researchers at the Broad Institute have dubbed the technology: REPAIR (RNA Editing for Programmable A to I Replacement). How does it work? To start, one has to understand the basics of transcription and translation. Here is a crude summary: DNA is transcribed to RNA which is then translated into proteins. This technology does not cut DNA, but instead, it binds to RNA and effectively changes one nucleoside in the RNA helix. Therefore, when RNA goes to translate into a protein, it will encode for a properly functioning protein instead of a mutant protein involved in disease progression. Amazing.

Woof, that was a lot of science. Thank you reading if you made it to the end. To conclude: CRISPR Technology holds incredible potential for ALS and other rare diseases. Researchers just need to perfect it in a lab so that when it is applied to humans, no one comes out missing a limb :).

Neil Clayton
Development Coordinator
MOFF is pleased to welcome Neil Clayton to the MOFF team as Development Coordinator and Strategic Thought Partner. Neil joins MOFF after working in law enforcement in San Luis Obispo County for over 20 years. During his law enforcement career, Neil volunteered with law enforcement-related non profits at both the local and state level. Neil recently retired from the SLO County District Attorney’s Office.

Neil supports MOFF’s mission and shares our organizational values having experienced the loss of a loved one to ALS in 2015. Driven by his experience with the challenges of caring for a loved one battling this disease locally, Neil is determined to help families living on the Central Coast find and maintain the medical care they need as well as do everything possible to support finding a cure.

In his spare time, Neil enjoys hiking, fishing and traveling with his wife Jennifer and their two children.

Gabriella Lyon
Social Media Coordinator
Gabriella is the Coordinator for Administrative Support at Associated Students, Inc. at Cal Poly San Luis Obispo. In her spare time, she serves as the Social Media Coordinator for MOFF. With a background in advocacy work and a personal understanding of the impact ALS has on families, Gabriella is committed to supporting and uplifting the ALS community. She holds a Bachelor of Arts degree in Communication and Sociology from the University of California, Davis.

Natalie Fernandez
Program Director, COO/CFO
Natalie is a Senior Consultant at Beghou Consulting. In her spare time she serves as Fractional COO/ CFO at MOFF. She is part of the Community Research Committee at the ALS Network and is a member of the Patient and Caregiver Advisory Committee at the ALS Association. Natalie holds an MBA degree in Pharmaceutical and Healthcare Business from the Philadelphia College of Pharmacy and an undergraduate degree from NYU. Natalie is motivated to find a cure for ALS to prevent individuals from experiencing what her mother, Martha, went through in her ALS journey. Natalie joined the ALS community when the saying was “ALS is not an incurable disease, it was just an underfunded one.” Today, it is now well funded. Let’s go! #findacureforALS

Andrea O'Brien
Board Member, Co-Founder, Secretary
Andrea O'Brien is a former HR professional who brings a wealth of experience in people and business to her role as Board Member, Co-Founder and Secretary at the Martha Olson-Fernandez Foundation. She holds a bachelor's degree from California Polytechnic State University and after building her professional career, she chose to dedicate her time to raising her son and daughter, embracing the opportunity to be present for their early years and family life. Her commitment to the Foundation is deeply personal, inspired by its namesake, her mother, Martha. Through her service, she honor's Martha's strength and resilience while advancing awareness, support and resources for individuals and families affected by ALS. She is proud to combine her professional experience and personal passion in support of the Foundation's mission.

John Ronca
Board Member
John joined the MOFF board of directors in April 2020. Bio coming soon.

Cheri Humphrey
Board Member
Cheri Humphrey joined the MOFF board of directors in August of 2019. Cheri grew up in Dixon, CA and moved to San Luis Obispo to attend Cal Poly. It was there that she met her husband Jim. They now reside in SLO and have a daughter, Victoria and a son, Riley. Cheri is instrumental in the operations of the iconic Madonna Inn, which she has been the Retail Manager of since 1989. Cheri and her family have been ALS advocates since the inception of MOFF. We are honored to have Cheri as part of the board to guide community outreach and continue raising awareness of ALS prevalence on the Central Coast.

Ian Parkinson
Board Member
We are very excited to welcome San Luis Obispo County Sheriff, Ian Parkinson, into his second two-year term as a member of the Martha Olson-Fernandez Foundation Board. Ian has served as Sheriff since 2011 and is well known in the community for this tireless efforts to improve the law enforcement processes of SLO County. Ian knew Martha Olson-Fernandez and has been a supporter of MOFF since 2012. We are very grateful for his commitment to help us carry out our mission to fight ALS through patient care and research. We look forward to utilizing his strategic insights and community outreach to further the MOFF mission.

Larry Fernandez
Director, CEO
Larry is a consultant in the vegetable seed industry. He has been an entrepreneur in the vegetable seed industry for 40 plus years. Larry is very proud of his daughter’s scholastic achievements, working careers and their growing families. He enjoys being a grandpa 3 times over, hunting and fishing when time permits. His goal in life is to honor his wife (Martha Olson-Fernandez) wishes of Finding a cure for ALS and assisting those living with ALS today so they never have to go through the processes she did while living with ALS.